DESCRIPTIVE RESEARCH REPORTS

Wednesday, October 16, 2013 - 4:00 pm – 6:45 pm and Thursday, October 17, 2013 - 11:30 am – 2:00 pm (optional)
Henry B. Gonzalez Convention Center - Hall A

Descriptive Research Reports poster abstracts describe new, improved or innovative roles or services in managed care pharmacy practice that are of such importance that they should be brought to the attention of other pharmacy professionals. The following poster abstracts were selected for presentation:

PRR-01: Allergen Immunotherapy Experience Among Participants of the Allergies, Immunotherapy and RhinoconjunctivitiS (AIRS) Patient Survey, Felicia Allen-Ramey, PhD, Executive Director, Global Health Outcomes, Merck & Co., Inc.

PRR-02: Interpreting Budget Impact Analyses in the United States: Can we do Better? Marc Botteman, MSc, Partner, Pharmerit North America

PRR-03: Breast Cancer Incidence Rate and Trastuzumab (Herceptin) Use Among 10 Million Commercially Insured Members, Kevin Bowen, MD, MBA, Senior Health Outcomes Researcher, Prime Therapeutics, LLC

PRR-04: The 2012 Distribution of Drug Cost by Member and Prevalence of Cancer Chemotherapy Among High Drug Cost Members: An Integrated Medical and Pharmacy Benefits Analysis of 10 Million Commercially Insured Members, Kevin Bowen, MD, MBA, Senior Health Outcomes Researcher, Prime Therapeutics, LLC

PRR-05: 2012 Prevalence and Cost of Coagulation Factor Treatment for Hemophilia and Von Willebrand’s Disease Among 10 Million Commercially Insured Members, Kevin Bowen, MD, MBA, Senior Health Outcomes Researcher, Prime Therapeutics, LLC

PRR-06: Defining Teriparatide Patient Population: Patient Characteristics, Sequence of Care, and Health Care Resources, Natalie Boytsov, PhD, Senior Research Scientist, Lilly USA, LLC
**PRR-07**: Axitinib U. S. Real World Dose Titration Experience from U. S. Specialty Pharmacy Data, Laura Cisar, PhD, Senior Director, Pfizer Inc.

**PRR-08**: Comparison of 3 mL Vials to 10 mL Vials and Prefilled Ppens of Rapid-Acting Insulin Analog on Pharmacy Budget in a Long-Term Care Setting, Elizabeth Eby, MPH, Research Scientist, Lilly USA, LLC

**PRR-09**: Use of National Quality Forum Measures in Rheumatoid Arthritis Patients in a Large Managed Care Population, Arlene Price, PharmD, Principal Scientist, Janssen Scientific Affairs, LLC

**PRR-10**: Attainment of National Quality Forum Measures by Rheumatoid Arthritis Patients Treated with DMARDs During 2010 or 2011, Arlene Price, PharmD, Principal Scientist, Janssen Scientific Affairs, LLC

**PRR-11**: The Use of Quality Indicators in Rheumatoid Arthritis Patients Receiving Methotrexate in a Large Managed Care Population, Arlene Price, PharmD, Principal Scientist, Janssen Scientific Affairs, LLC

**PRR-12**: Demographic and Clinical Characteristics of Patients Before Initiating Adalimumab, Etanercept or Golimumab, Brian Macomson, PharmD, Principal Scientist, Janssen Scientific Affairs, LLC

**PRR-13**: Health Resource Utilization and Costs Before and After Abiraterone Acetate (AA) Initiation in Chemotherapy-Experienced Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC), Brian Macomson, PharmD, Principal Scientist, Janssen Scientific Affairs, LLC

**PRR-14**: Observed Abiraterone Acetate Utilization by Prostate Cancer (PC) Patients in a Large U. S. Administrative Claims Database: Commercial and Medicare Perspectives, Brian Macomson, PharmD, Principal Scientist, Janssen Scientific Affairs, LLC

**PRR-15**: Impact of Stroke and Hemorrhage on First-Year Healthcare Costs After Diagnosis with Non-Valvular Atrial Fibrillation Among Medicare Patients, Jonah Broulette, ASA, MAAA, Associate Actuary, Milliman, Inc.
PRR-16: Persistence and Discontinuation Among Newly Initiated Kinase Inhibitor Treated Patients for One Year Post Initiation, Haita Makanji, PharmD, Manager, Clinical Programs, CDMI, LLC

PRR-17: Effects of an Outpatient Generic Medication Voucher Program on the Generic Dispensing Ratio (GDR) in a 4,100 Physician-Hospital Organization (PHO) - 4 Years Experience, Mark Greg, PharmD, RPh, Clinical Pharmacist, Pharmacy Programs, Advocate Physician Partners

PRR-18: Understanding Reasons for Non-Adherence to Medications in a Medicare Part D Beneficiary Sample: A Pilot Study, Ana Hincapie, PhD, Assistant Professor, California Northstate University, College of Pharmacy

PRR-19: Assessing Janus Kinase Inhibitor’s Place in Therapy in Established Rheumatoid Arthritis Patients – from a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors to a Bayesian Probability of Response – The Value of Transparency, Arlene Price, Liaison, Medical Science, Janssen Scientific Affairs, LLC

PRR-20: Dissecting the Dossier: Utility and Challenges 13 Years Later, James Jackson, PharmD, MPH, Vice President, Xcenda, LLC

PRR-21: Daily Dose and Costs Associated with Maintenance Therapy of Topical Testosterone Agents, Anna Kaltenboeck, MA, Manager, Analysis Group, Inc.

PRR-22: Treatment Patterns and Costs Associated with Acne in the United States, James Kendall, PharmD, Managed Care Medical Science Liaison, Galderma Laboratories, L.P.

PRR-23: Treatment Patterns and Costs Associated with Rosacea in the United States, James Kendall, PharmD, Managed Care Medical Science Liaison, Galderma Laboratories, L.P.

PRR-24: Costs Associated with Adverse Events Among Patients Treated for Chronic Hepatitis C Virus, Stephen Sander, PharmD, Associate Director, Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc.
PRR-25: Costs Associated with Advanced Liver Disease Among Commercially-Insured Patients with Chronic Hepatitis C Virus, Stephen Sander, PharmD, Associate Director, Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc.

PRR-26: Pulmonary Hypertension Related Rehospitalizations Among Medicare Advantage or Commercially Insured Patients with Pulmonary Hypertension, William Drake, PharmD, US Medical, Managed Markets and Health Economics and Outcomes Research, Actelion Pharmaceuticals US, Inc.


PRR-28: Evaluation of Therapy Completion and Adverse Event Rates of Hepatitis C Patients Treated with Protease Inhibitor Therapy, Erin Lopata, PharmD, Coordinator, Specialty Pharmacy, University of Pittsburgh Medical Center (UPMC) Health Plan

PRR-29: Evaluation of Glycemic Control, Diabetes-Related Costs and Persistence Between GLP-1 Agonists Liraglutide and Exenatide at 6 Months: A Retrospective Claims Database Analysis, Erin K. Buysman, MS, Associate Director, Health Economics and Outcomes Research, OptumInsight

PRR-30: Incremental Healthcare Resource Utilization and Fractures Associated with Non-Compliance to Anti-Osteoporosis Medications: Analysis of a U.S. Managed Care Population, Ankita Modi, PhD, Director, Global Health Outcomes, Merck & Co., Inc.

PRR-31: Factors Associated with High Cost Multiple Sclerosis Patients in a Commercially Insured U.S. Population, Prakash Navaratnam, RPh, MPH, PhD, Senior Partner and Director, Business Development, DataMed Solutions

PRR-32: The Majority of Patients Cannot Complete Protease-Inhibitor Based Hepatitis C Virus (HCV) Therapy: Analysis of a Large Real World U.S. Cohort, Yoona Kim, PharmD, Associate Director, Health Economics and Outcomes Research, Gilead Sciences, Inc.

PRR-33: Impact of Adherence with Urinary Antispasmodic Medications on Healthcare Costs, Absenteeism and Worker Productivity, Kevin Odell, PharmD, RPh, Director Medical Affairs, Pfizer Inc.
**PRR-34:** Understanding Predictors of Opioid Abuse: Predictive Model Development and Validation, Margaret Pasquale, PhD, Principal Researcher, Comprehensive Health Insights, A Humana Company

**PRR-35:** Are There Differences in Treatment Patterns and Costs by Treatment Setting and Insurance Type? Carolina Reyes, PhD, Associate Director, Health Economics and Outcomes Research, Genentech, A Member of the Roche Group

**PRR-36:** Annual Cost Per Treated Patient for Biologics in Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis in a Pharmacy Benefit Management Setting, David Harrison, PhD, Director, Global Health Economics, Amgen Inc.

**PRR-37:** Outcome Evaluation of a PBM Based Asthma Management Program, Julie Simani, DNP, MS, RN, CQIA, Senior Manager Clinical Programs, Navitus Health Solutions

**PRR-38:** Medical Cost Differences Associated with Adherence and Non-Adherence to Specialty Medications, John Smolskis, MA, Senior Research Consultant, OptumInsight

**PRR-39:** Short-Term Disability (STD) Associated with Bone Metastasis (BM) in Commercially Insured Patients with Solid Tumors, Yi Qian, PhD, Senior Manager, Amgen Inc.

**PRR-40:** Risk of Injury in Elderly Patients Using Gastrointestinal Antispasmodic/Anticholinergic Drugs, Michele Spence, PhD, Clinical Pharmacy Research Scientist, Kaiser Permanente

**PRR-41:** Identifying Members with High Risk Opioid Utilization Using Commercial Health Insurance Claims, Catherine Starner, PharmD, Senior Health Outcomes Researcher, Prime Therapeutics LLC, College of Pharmacy University of Minnesota

**PRR-42:** Specialty Drugs Pharmaceutical Manufacturer Coupons and Patient Assistance Programs Contribution to Member Share Among 10 Million Commercially Insured Members, Catherine Starner, PharmD, Senior Health Outcomes Researcher, Prime Therapeutics LLC, College of Pharmacy University of Minnesota
PRR-43: Controlled Substances Retrospective Drug Utilization Review: Outcomes from a Concurrent Cohort Study, Catherine Starner, PharmD, Senior Health Outcomes Researcher, Prime Therapeutics LLC, College of Pharmacy University of Minnesota


PRR-45: Healthcare Costs Among Patients with Uncontrolled Epilepsy Despite Adjunctive Therapy: A Retrospective Study in a U.S. Commercially-Insured Population, Fulton Velez, MD, MS, Director, Health Economics and Outcomes Research, Sunovion Pharmaceuticals Inc.

PRR-46: Low Treatment Rate with Anti-Osteoporosis Medications Among Women Diagnosed with Osteoporosis in the United States Medicare Population, Ankita Modi, PhD, Director, Global Health Outcomes, Merck & Co., Inc.